Theressa J. Wright - Concepedia

Author

Theressa J. Wright

Eli Lilly (United States)

Also Known As

T Wright, Theressa J Wright, Theressa J. Wright, Theressa Wright

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

Eli Lilly (United States)Vanderbilt University

About

Theressa J. Wright is an author at Eli Lilly (United States) specializing in medicine, pharmacotherapy, and cardiovascular disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	631
2	Clinical Trials	2	2	176
3	Pharmacology	1	1	166
4	Clinical Microbiology	1	1	257
5	Diuretic Resistance	1	1	32

Theressa J. Wright

Publications

1.7K

Citations

H-Index

Page 1

	Year	Citations
Adverse Mortality Effect of Central Sympathetic Inhibition with Sustained-Release Moxonidine in Patients with Heart Failure (MOXCON) Jay N. Cohn, Marc A. Pfeffer, Jean L. Rouleau, European Journal of Heart Failure	2003	378
Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment* Jean‐Louis Vincent, Gordon R. Bernard, Richard Beale, Critical Care Medicine	2005	320
Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis Gordon R. Bernard, E. Wesley Ely, Theressa J. Wright, Critical Care Medicine	2001	271
Low Levels of Protein C Are Associated With Poor Outcome in Severe Sepsis S. Betty Yan, Jeffrey D. Helterbrand, Daniel Hartman, CHEST Journal InflammationSevere SepsisPoor OutcomeDisease PathophysiologyInflammatory Marker	2001	257
Design and methods of the Raloxifene Use for The Heart (RUTH) study Lori Mosca, Elizabeth Barrett‐Connor, Nanette K. Wenger, The American Journal of Cardiology Heart FailureRaloxifene UseCardiovascular DiseaseMedicinePharmacotherapy	2001	166
Extended Evaluation of Recombinant Human Activated Protein C United States Trial (ENHANCE US) Gordon R. Bernard, Benjamin D. Margolis, Harvey M. Shanies, CHEST Journal Translational MedicineExtended EvaluationEnhance UsClinical TrialsTranslational Research	2004	162
Effects of Sustained-Release Moxonidine, an Imidazoline Agonist, on Plasma Norepinephrine in Patients With Chronic Heart Failure Karl Swedberg, Michael R. Bristow, Jay N. Cohn, Circulation	2002	102
The effects of chronic, sustained-release moxonidine therapy on clinical and neurohumoral status in patients with heart failure Kenneth Dickstein, Cord Manhenke, Torbjørn Aarsland, International Journal of Cardiology Heart FailureCardiovascular DiseaseSustained-release Moxonidine TherapyCardiovascular PharmacologyNeurohumoral Status	2000	32
Analysis of reports of human exposure to Micotil 300 (tilmicosin injection) Melissa Veenhuizen, Theressa J. Wright, Robert F McManus, Journal of the American Veterinary Medical Association	2006	24
Baseline Characteristics and Survival of Adult Severe Sepsis Patients Treated With Drotrecogin Alfa (Activated) in a Global, Single-Arm, Open-Label Trial (ENHANCE Arthur P. Wheeler, Christopher Doig, Theressa J. Wright, CHEST Journal Open-label TrialAcute CareClinical TrialsSepsisTranslational Research	2003	14

Page 1